148 related articles for article (PubMed ID: 19364699)
1. Editorial: What have we lost in the wake of the rosiglitazone controversy?
Zarich SW; Nesto RW
Endocr Pract; 2009 Apr; 15(3):273-4. PubMed ID: 19364699
[No Abstract] [Full Text] [Related]
2. Clinical practice effect of rosiglitazone discontinuation on glycemic control.
Fanning EL; Weissman PN; Menditto LA
Endocr Pract; 2009 Apr; 15(3):270-2. PubMed ID: 19364698
[No Abstract] [Full Text] [Related]
3. In brief: rosiglitazone (Avandia) unbound.
Med Lett Drugs Ther; 2014 Feb; 56(1435):12. PubMed ID: 24662977
[No Abstract] [Full Text] [Related]
4. [Doubts as to the cardiovascular safety of rosiglitazone].
Wolffenbuttel BH
Ned Tijdschr Geneeskd; 2007 Oct; 151(40):2236-7; author reply 2237. PubMed ID: 17969577
[No Abstract] [Full Text] [Related]
5. The safety of rosiglitazone in the treatment of type 2 diabetes.
Singh S; Loke YK
Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
McGuire DK
Diab Vasc Dis Res; 2007 Jun; 4(2):77-9. PubMed ID: 17654438
[No Abstract] [Full Text] [Related]
7. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
Erdmann E; Scherbaum WA
MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
[No Abstract] [Full Text] [Related]
8. Rosiglitazone and heart failure: the controversy and clinical implications.
Virk IS; Ruby RS; Tepper D
Congest Heart Fail; 2007; 13(5):293-5. PubMed ID: 17917497
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
10. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
11. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
12. Cardiovascular safety of rosiglitazone.
Krall RL
Lancet; 2007 Jun; 369(9578):1995-1996. PubMed ID: 17574083
[No Abstract] [Full Text] [Related]
13. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
Odom J; Williamson B; Carter L
Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
[No Abstract] [Full Text] [Related]
14. [Doubts as to the cardiovascular safety of rosiglitazone].
Hoekstra JB; Bossuyt PM; de Vries JH
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1449-50. PubMed ID: 17633972
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone: seeking a balanced perspective.
The Lancet
Lancet; 2007 Jun; 369(9576):1834. PubMed ID: 17544746
[No Abstract] [Full Text] [Related]
16. Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
[No Abstract] [Full Text] [Related]
17. Pioglitazone is a valid alternative to rosiglitazone.
Derosa G
Am J Cardiovasc Drugs; 2011 Dec; 11(6):357-62. PubMed ID: 21950735
[TBL] [Abstract][Full Text] [Related]
18. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
Stockl KM; Le L; Zhang S; Harada AS
Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
[TBL] [Abstract][Full Text] [Related]
19. The new rosiglitazone story: its place today in type 2 diabetes management.
Ambery P; Pandya B
Prim Care Diabetes; 2009 Feb; 3(1):57-9. PubMed ID: 19269912
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
Boyle P
South Med J; 2007 Nov; 100(11):1063-4. PubMed ID: 17984728
[No Abstract] [Full Text] [Related]
[Next] [New Search]